News | News By Subject | News by Disease News By Date | Search News

Renal Cell Carcinoma News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Bristol-Myers Squibb (BMY) Grabs Breakthrough Tag for Opdivo     9/16/2015
Revitalized Exelixis (EXEL) Grabs Breakthrough Tag for Cabozantinib     8/25/2015
Bristol-Myers Squibb (BMY)'s Opdivo Phase III Study Stopped Early on More Good Cancer Therapy News     7/21/2015
Embattled Exelixis (EXEL) Nabs Much-Needed Victory for Phase III Renal Cell Carcinoma Study     7/21/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test     3/19/2014
FDA Committee Turns Down AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO)/Astellas Pharma Inc. (YPH.BE)'s Cancer Drug     5/6/2013
Pfizer Inc. (PFE) Kidney Cancer Drug Fails as Initial Treatment     10/18/2012
Pfizer Inc. (PFE)'s Torisel Drug Fails in a Combination Study     8/13/2012
Pfizer Inc. (PFE)'s Torisel Fails Phase III Renal Cell Carcinoma Study in Showdown Against Bayer HealthCare (BAY)'s Nexavar     5/16/2012
Argos Therapeutics, Inc. Raises $25 Million Series D Financing     4/24/2012
AVEO Pharmaceuticals, Inc. (AVEO) Announces Publication of Positive Tivozanib Phase 2 Clinical Trial Results in Journal of Clinical Oncology     4/12/2012
FDA Approves Pfizer Inc. (PFE)'s INLYTA® (axitinib) for Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)     1/30/2012
Pfizer Inc. (PFE) Receives Backing for Late-stage Trial of Kidney Cancer Drug in Asia     1/9/2012

News from Around the Web

Press Releases
Exelixis (EXEL) Announces Positive Results From METEOR Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Presented At European Cancer Congress 2015     9/28/2015
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Demonstrates Superior Overall Survival In A Phase 3 Trial Compared To Standard Of Care In Patients With Previously Treated Advanced Renal Cell Carcinoma     9/28/2015
Exelixis (EXEL) Release: Data From METEOR Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma Accepted As Late-Breaker Presentation In Presidential Session At European Cancer Congress 2015     8/24/2015
Argos Therapeutics, Inc. (ARGS) Reports Second Quarter 2015 Financial Results And Operational Highlights     8/13/2015
Argos Therapeutics, Inc. (ARGS) Announces Pilot Clinical Trial Of AGS-003 As Neoadjuvant Immunotherapy For Localized Renal Cell Carcinoma     8/10/2015
AVEO Oncology (AVEO) Reports Second Quarter 2015 Financial Results     8/10/2015
Argos Therapeutics, Inc. (ARGS) Announces Completion Of Patient Enrollment In Pivotal Phase III ADAPT Clinical Trial Of AGS-003     7/15/2015
Argos Therapeutics, Inc. (ARGS) Release: Independent Data Monitoring Committee Recommends Continuation Of Pivotal ADAPT Phase III Clinical Trial Of AGS-003 For Metastatic Renal Cell Carcinoma     6/4/2015
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Demonstrate Survival Benefit Of First-Line Proleukin Therapy In Patients With Metastatic Renal Cell Carcinoma     5/28/2015
TRACON Pharmaceuticals, Inc. (TCON)'s TRC105 Receives FDA Fast Track Designation     5/15/2015
Argos Therapeutics, Inc. (ARGS) Provides Update On Enrollment Progress For Ongoing Pivotal Phase III ADAPT Clinical Trial     5/14/2015
Cerulean Pharma Inc. (CERU) Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma     4/28/2015
Argos Therapeutics, Inc. (ARGS) Announces Publication Of Data From Phase 2 Clinical Trial Of AGS-003 Fully Personalized Immunotherapy For Treatment Of Metastatic Renal Cell Carcinoma (mRCC)     4/21/2015
Peloton Therapeutics Presents Promising Data On First Inhibitor Of HIF-2a For Renal Cell Carcinoma At 2015 AACR Annual Meeting     4/20/2015
Exelixis, Inc. (EXEL)’s Cabozantinib Granted Fast Track Designation By FDA For Advanced Renal Cell Carcinoma     4/9/2015